Literature DB >> 21071147

Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence.

Laurence Meyer1, Christine Patte-Mensah, Omar Taleb, Ayikoe Guy Mensah-Nyagan.   

Abstract

Oxaliplatin (OXAL) is a platinum-based drug used for the treatment of colorectal, lung, breast and ovarian cancers. OXAL does not cause renal or hematologic toxicity. However, OXAL induces neuropathic pain which hampers the chemotherapy success. Attempts with neuroprotective agents including anticonvulsivants and antidepressants were made to prevent OXAL-induced painful neuropathy but the clinical data are controversial and the tested neuroprotectors are able to evoke themselves undesirable effects. Here, we demonstrated that the natural neurosteroid allopregnanolone (3α,5α-THP), known to be devoid of toxic side-effects in humans and experimental models, prevented and suppressed OXAL-induced painful neuropathic symptoms. Indeed, 3α,5α-THP repaired OXAL-evoked neurochemical and functional alterations in peripheral nerves and intra-epidermal nerve fibers (IENF). Behavioral analyses showed that prophylactic or corrective 3α,5α-THP treatment (4mg/kg/2days) respectively prevented or abolished OXAL-induced cold allodynia, mechanical allodynia and hyperalgesia by reversing to normal decreased thermal and mechanical pain thresholds of OXAL-treated rats. Electrophysiological investigations revealed that 3α,5α-THP restored control values of sciatic nerve conduction velocity and action potential peak amplitude drastically reduced by OXAL-treatment. Furthermore, immunohistochemistry and confocal microscopic quantifications demonstrated that 3α,5α-THP repaired OXAL-induced neurochemical/cellular alterations by restoring IENF control density and normal level of neurofilament 200kDa that was strongly repressed by OXAL in dorsal root ganglion neurons and sciatic nerve axons. OXAL showed no toxicity for the non-compact myelin protein 2',3'-cyclic-nucleotide-3'-phosphodiesterase whose expression level was similarly increased by 3α,5α-THP in controls and OXAL-treated rat nerves. Together, these results may be interesting for the development of natural or safe neurosteroid-based neuroprotective strategy against anticancer drug-evoked painful neuropathy.
Copyright © 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071147     DOI: 10.1016/j.pain.2010.10.015

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  35 in total

1.  DNA molecular recognition and cellular selectivity of anticancer metal(II) complexes of ethylenediaminediacetate and phenanthroline: multiple targets.

Authors:  Sze-Tin Von; Hoi-Ling Seng; Hong-Boon Lee; Seik-Weng Ng; Yusuke Kitamura; Makoto Chikira; Chew-Hee Ng
Journal:  J Biol Inorg Chem       Date:  2011-08-11       Impact factor: 3.358

2.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.

Authors:  W H Xiao; H Zheng; G J Bennett
Journal:  Neuroscience       Date:  2011-12-20       Impact factor: 3.590

4.  Evidences for antinociceptive effect of 17-α-hydroxyprogesterone caproate in carpal tunnel syndrome.

Authors:  Federica Ginanneschi; Paolo Milani; Georgios Filippou; Mauro Mondelli; Bruno Frediani; Roberto C Melcangi; Alessandro Rossi
Journal:  J Mol Neurosci       Date:  2011-11-24       Impact factor: 3.444

5.  Beneficial effects of Gelsemium-based treatment against paclitaxel-induced painful symptoms.

Authors:  Ludivine Vitet; Christine Patte-Mensah; Naoual Boujedaini; Ayikoé-Guy Mensah-Nyagan; Laurence Meyer
Journal:  Neurol Sci       Date:  2018-09-24       Impact factor: 3.307

Review 6.  Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective.

Authors:  Susana Laura González; Laurence Meyer; María Celeste Raggio; Omar Taleb; María Florencia Coronel; Christine Patte-Mensah; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Neurobiol       Date:  2018-09-05       Impact factor: 5.046

7.  Role of neuroactive steroids in the peripheral nervous system.

Authors:  Roberto Cosimo Melcangi; Silvia Giatti; Marzia Pesaresi; Donato Calabrese; Nico Mitro; Donatella Caruso; Luis Miguel Garcia-Segura
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-27       Impact factor: 5.555

8.  Impact of Dose, Sex, and Strain on Oxaliplatin-Induced Peripheral Neuropathy in Mice.

Authors:  Urszula O Warncke; Wisam Toma; Julie A Meade; Abigail J Park; Danielle C Thompson; Martial Caillaud; John W Bigbee; Camron D Bryant; M Imad Damaj
Journal:  Front Pain Res (Lausanne)       Date:  2021-07-22

9.  A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy.

Authors:  Lauren E Ta; James D Schmelzer; Allan J Bieber; Charles L Loprinzi; Gary C Sieck; Jill D Brederson; Philip A Low; Anthony J Windebank
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

Review 10.  Allopregnanolone: An overview on its synthesis and effects.

Authors:  Silvia Diviccaro; Lucia Cioffi; Eva Falvo; Silvia Giatti; Roberto Cosimo Melcangi
Journal:  J Neuroendocrinol       Date:  2021-06-29       Impact factor: 3.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.